OCUL

8.23

0.12% 0.010

Dopo l'orario di chiusura: 8.50 0.27 +3.28%

Ocular Therapeutix Inc (OCUL)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché OCUL Giù? Forum Previsione

Precedente Chiudi:

$8.22

Aprire:

$8.23

Volume 24 ore:

2.03M

Relative Volume:

0.48

Capitalizzazione di mercato:

$1.80B

Reddito:

$52.04M

Utile/perdita netta:

$-290.50M

Rapporto P/E:

-7.762

EPS:

-1.0603

Flusso di cassa netto:

$-216.89M

1 W Prestazione:

-10.15%

1M Prestazione:

-14.80%

6M Prestazione:

-32.76%

1 anno Prestazione:

+14.07%

Intervallo 1D:

$8.1193

$8.36

Intervallo di 1 settimana:

$7.86

$9.245

Portata 52W:

$6.2301

$16.44

Ocular Therapeutix Inc Stock (OCUL) Company Profile

Nome

Ocular Therapeutix Inc

Settore

Healthcare (1108)

Industria

Biotechnology (618)

Telefono

781-357-4000

Indirizzo

14 CROSBY DRIVE, 3RD FLOOR, BEDFORD, MA

Dipendente

325

Cinguettio

@OCUTX

Prossima data di guadagno

2026-05-05

Ultimi documenti SEC

OCUL's Discussions on Twitter

Compare OCUL vs VRTX, REGN, ARGX, ALNY, RVMD

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
OCUL Ocular Therapeutix Inc	8.23	1.80B	52.04M	-290.50M	-216.89M	-1.0603
VRTX Vertex Pharmaceuticals Inc	434.52	110.03B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	638.88	67.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	806.46	50.76B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	297.45	40.12B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	151.56	32.68B	742.00K	-1.37B	-1.07B	-7.0731

Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-09-15	Iniziato	Chardan Capital Markets	Buy
2025-04-08	Iniziato	William Blair	Outperform
2025-03-18	Iniziato	RBC Capital Mkts	Outperform
2025-03-11	Iniziato	Needham	Buy
2024-10-16	Iniziato	Scotiabank	Sector Outperform
2024-06-20	Aggiornamento	TD Cowen	Hold → Buy
2024-05-31	Ripresa	Piper Sandler	Overweight
2024-02-09	Iniziato	BofA Securities	Buy
2023-04-21	Iniziato	Robert W. Baird	Outperform
2022-08-10	Ripresa	Berenberg	Buy
2021-08-10	Aggiornamento	H.C. Wainwright	Neutral → Buy
2020-12-28	Downgrade	H.C. Wainwright	Buy → Neutral
2020-12-17	Iniziato	Berenberg	Buy
2020-11-13	Reiterato	Raymond James	Strong Buy
2020-08-10	Reiterato	H.C. Wainwright	Buy
2020-03-03	Aggiornamento	Raymond James	Outperform → Strong Buy
2019-05-21	Downgrade	Cowen	Outperform → Market Perform
2019-05-21	Reiterato	H.C. Wainwright	Buy
2019-05-21	Downgrade	Raymond James	Strong Buy → Outperform
2018-12-03	Reiterato	Cantor Fitzgerald	Overweight
2018-11-15	Iniziato	Raymond James	Strong Buy
2018-09-07	Iniziato	Piper Jaffray	Overweight
2017-10-24	Iniziato	Guggenheim	Buy
2017-07-26	Iniziato	H.C. Wainwright	Buy
2017-07-12	Reiterato	Cantor Fitzgerald	Overweight
2017-06-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2017-02-10	Iniziato	Cantor Fitzgerald	Overweight
2016-11-15	Reiterato	RBC Capital Mkts	Outperform
2016-08-11	Iniziato	JMP Securities	Mkt Outperform
2016-02-17	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2015-10-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2015-08-13	Iniziato	Morgan Stanley	Overweight

Mostra tutto

Ocular Therapeutix Inc Borsa (OCUL) Ultime notizie

May 24, 2026

Q3 2025 Ocular Therapeutix Inc Earnings Call Transcript - GuruFocus

May 24, 2026

Q2 2025 Ocular Therapeutix Inc Earnings Call Transcript - GuruFocus

May 24, 2026

Ocular Therapeutix Inc at Bank of America Global Healthcare Conference Transcript - GuruFocus

May 24, 2026

May 22, 2026

OCUL Stock Price, Quote & Chart | OCULAR THERAPEUTIX INC (NASDAQ:OCUL) - ChartMill

May 22, 2026

May 20, 2026

Selling Ocular Therapeutix Shares at a Lower Price Than Current Market Value May Have Been a Costly Mistake for Insiders - Moomoo

May 20, 2026

May 19, 2026

Can Ocular Therapeutix's (OCUL) Rising Losses on Flat Revenue Still Support Its R&D Ambitions? - simplywall.st

May 19, 2026

What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors - The Globe and Mail

May 19, 2026

What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors - The Motley Fool

May 19, 2026

May 17, 2026

Why (OCUL) Price Action Is Critical for Tactical Trading - Stock Traders Daily

May 17, 2026

May 15, 2026

[SCHEDULE 13G/A] OCULAR THERAPEUTIX, INC Amended Passive Investment Disclosure - Stock Titan

May 15, 2026

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

May 15, 2026

New HR boss at Ocular Therapeutix lands 75,000 stock options, 25,000 RSUs - Stock Titan

May 15, 2026

May 13, 2026

Dole posts downbeat Q1 earnings, joins Ocular Therapeutix and other big stocks moving lower in Monday's pre-market session - MSN

May 13, 2026

Neuropathic Ocular Pain Therapeutics Market Size (7MM) - openPR.com

May 13, 2026